Latest

1 story

Hide weekly roundups

Friday, July 24

Immunomic Therapeutics opens Phase 1 trial of ITI-9001 for Japanese Red Cedar pollinosis

Trial updateImmunomic Therapeutics, Inc

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.